- Illustrations
- Specialized Illustrations
- Disease-specific
- Malignant Tumor Affecting a Breast Lymph Node
Malignant Tumor Affecting a Breast Lymph Node
A female breast featuring a cancer node.
jpg, png
exc.VAT*
Prices are displayed excluding VAT. VAT will be calculated during checkout based on your business location and VAT number validity.
Description
Sectioned breast tissue is rendered in cross-section, with glandular lobules and terminal ductal units positioned deep to the skin and embedded within subcutaneous adipose tissue. Lactiferous ducts course anteriorly and converge toward the nipple, while Cooper’s ligaments run as fibrous septa from dermis to deep fascia, tethering the parenchyma. A malignant tumor focus involves a breast lymph node, shown adjacent to the ductal-lobular tissue and within the expected lymphatic drainage pathway that tracks laterally and superiorly toward the axilla. Lymph node involvement is a staging inflection point in breast cancer, and this view makes the relationship between primary mammary parenchyma and nodal disease easier to teach than an isolated node diagram. Intramammary and axillary nodes act as waystations for metastasis from invasive ductal carcinoma and invasive lobular carcinoma, so a highlighted cancer node directly supports discussions of sentinel lymph node biopsy, pathologic nodal status (pN), and why nodal metastases often precede distant spread. Small details matter. Retraction or peau d’orange can be explained here by tumor infiltration of Cooper’s ligaments and obstruction of dermal lymphatics. Use this illustration in anatomy and surgery teaching on breast lymphatic drainage, in oncology or pathology modules covering regional nodal staging, or in patient-facing materials that need a clear correlation between the mammary ducts, supporting stroma, and a cancer-involved lymph node. It also fits breast imaging and interventional radiology content when introducing the rationale for sentinel node mapping and targeted axillary dissection. Anatomical accuracy verified by SciePro's Medical Advisory Board.